No association between vitamin K epoxide reductase complex subunit 1-like 1 (VKORC1L1) and the variability of warfarin dose requirement in a Japanese patient population

Thrombosis Research

Volumn 122, Issue 2, 2008, Pages 179-184

  Yin, Tong ^a   Hanada, Hironori ^a   Miyashita, Kotaro ^a   Kokubo, Yoshihiro ^a   Akaiwa, Yasuhisa ^a   Otsubo, Ryoichi ^a   Nagatsuka, Kazuyuki ^a   Otsuki, Toshiho ^a   Okayama, Akira ^a   Minematsu, Kazuo ^a   Naritomi, Hiroaki ^a   Tomoike, Hitonobu ^a   Miyata, Toshiyuki ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; MENADIONE EPOXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); WARFARIN;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CEREBROVASCULAR ACCIDENT; CHROMOSOME 7Q; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE CONSTRUCT; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROPHYLAXIS; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AMINO ACID SEQUENCE; FEMALE; HAPLOTYPES; HUMANS; JAPAN; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MOLECULAR SEQUENCE DATA; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE HOMOLOGY, AMINO ACID; WARFARIN;

EID: 44449095581     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.09.015     Document Type: Article

References (25)

1. Hirsh J., Fuster V., Ansell J., and Halperin J.L. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107 (2003) 1692-1711
2. Gage B.F. Pharmacogenetics-based coumarin therapy. Hematology Am Soc Hematol Educ Program (2006) 467-473
3. Yin T., and Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives. Thromb Res 120 (2007) 1-10
4. Millican E., Jacobsen-Lenzini P.A., Milligan P.E., Grosso L., Eby C., Deych E., Grice G., Clohisy J.C., Barrack R.L., Burnett R.S., Voora D., Gatchel S., Tiemeier A., and Gage B.F. Genetic-based dosing in orthopaedic patients beginning warfarin therapy. Blood 110 (2007) 1511-1515
5. Rieder M.J., Reiner A.P., Gage B.F., Nickerson D.A., Eby C.S., McLeod H.L., Blough D.K., Thummel K.E., Veenstra D.L., and Rettie A.E. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 (2005) 2285-2293
6. Geisen C., Watzka M., Sittinger K., Steffens M., Daugela L., Seifried E., Muller C.R., Wienker T.F., and Oldenburg J. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94 (2005) 773-779
7. Marsh S., King C.R., Porche-Sorbet R.M., Scott-Horton T.J., and Eby C.S. Population variation in VKORC1 haplotype structure. J Thromb Haemost 4 (2006) 473-474
8. Osman A., Enstrom C., Arbring K., Soderkvist P., and Lindahl T.L. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J Thromb Haemost 4 (2006) 1723-1729
9. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hortnagel K., Pelz H.J., Lappegard K., Seifried E., Scharrer I., Tuddenham E.G., Muller C.R., Strom T.M., and Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 (2004) 537-541
10. Li T., Chang C.Y., Jin D.Y., Lin P.J., Khvorova A., and Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427 (2004) 541-544
11. Wajih N., Sane D.C., Hutson S.M., and Wallin R. Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system. J Biol Chem 280 (2005) 10540-10547
12. Rost S., Fregin A., Hunerberg M., Bevans C.G., Muller C.R., and Oldenburg J. Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb Haemost 94 (2005) 780-786
13. Wajih N., Hutson S.M., and Wallin R. Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction. J Biol Chem 282 (2007) 2626-2635
14. Wadelius M., Chen L.Y., Eriksson N., Bumpstead S., Ghori J., Wadelius C., Bentley D., McGinnis R., and Deloukas P. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121 (2007) 23-34
15. Consortium. TIH. A haplotype map of the human genome. Nature 437 (2005) 1299-1320
16. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
17. de Bakker P.I., Yelensky R., Pe'er I., Gabriel S.B., Daly M.J., and Altshuler D. Efficiency and power in genetic association studies. Nat Genet 37 (2005) 1217-1223
18. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 31 (2000) 817-821
19. Chimowitz M.I., Lynn M.J., Howlett-Smith H., Stern B.J., Hertzberg V.S., Frankel M.R., Levine S.R., Chaturvedi S., Kasner S.E., Benesch C.G., Sila C.A., Jovin T.G., and Romano J.G. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352 (2005) 1305-1316
20. Kimura R., Miyashita K., Kokubo Y., Akaiwa Y., Otsubo R., Nagatsuka K., Otsuki T., Okayama A., Minematsu K., Naritomi H., Honda S., Tomoike H., and Miyata T. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120 (2007) 181-186
21. Tanaka C., Kamide K., Takiuchi S., Miwa Y., Yoshii M., Kawano Y., and Miyata T. An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene polymorphisms. Hypertens Res 26 (2003) 301-306
22. Chu P.H., Huang T.Y., Williams J., and Stafford D.W. Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2. Proc Natl Acad Sci U S A 103 (2006) 19308-19313
23. Kimura R., Kokubo Y., Miyashita K., Otsubo R., Nagatsuka K., Otsuki T., Sakata T., Nagura J., Okayama A., Minematsu K., Naritomi H., Honda S., Sato K., Tomoike H., and Miyata T. Polymorphisms in vitamin K-dependent gamma-carboxylation-related genes influence interindividual variability in plasma protein C and protein S activities in the general population. Int J Hematol 84 (2006) 387-397
24. Gibbs R. Deeper into the genome. Nature 437 (2005) 1233-1234
25. Topol E.J., and Frazer K.A. The resequencing imperative. Nat Genet 39 (2007) 439-440